ヒトマイクロバイオーム市場：現状分析と予測（2022年～2028年）

世界のヒトマイクロバイオームの市場規模は、予測期間中に約26.7％の大幅な成長率で成長すると予測されています。人体内に存在する微生物の数は、がんなどの疾患の管理や新しい治療法の導入に有益であると、研究によって考えられています。これは、ヒトマイクロバイオーム市場を急成長させる医薬品開発者とワクチン製造業者に有利な機会を提供しています。

当レポートでは、世界のヒトマイクロバイオーム市場について調査し、COVID-19の影響、セグメント別の市場洞察、市場機会や動向、主要企業のプロフィールなどの情報を提供しています。

目次

第1章 市場イントロダクション

第2章 調査手法/前提条件

第3章 市場要約

第4章 エグゼクティブサマリー

第5章 COVID-19のヒトマイクロバイオーム市場への影響

第6章 ヒトマイクロバイオーム市場収益（2020年～2028年）

第7章 市場洞察：製品タイプ別

• プロバイオティクス
• プレバイオティクス
• 診断テスト
• 医薬品
• メディカルフーズ
• サプリメント
• その他

第8章 市場洞察：用途別

• 治療
• 診断

第9章 市場洞察：疾患別

• 肥満症
• 感染症
• 自己免疫疾患
• 代謝・胃腸障害
• がん
• その他

第10章 市場洞察：流通チャネル別

• 小売薬局
• 病院薬局
• オンライン薬局

第11章 市場洞察：地域別

• 北米
  • 米国
  • カナダ
  • その他
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他
• その他の地域

第12章 ヒトマイクロバイオーム市場力学

• 市場促進要因
• 市場の課題
• 影響分析

第13章 ヒトマイクロバイオームの市場機会

第14章 ヒトマイクロバイオームの市場動向

第15章 需要側と供給側の分析

• 需要側分析
• 供給側分析

第16章 バリューチェーン分析

第17章 競合シナリオ

• 競合情勢
  • ポーターのファイブフォース分析

第18章 企業プロファイル

• Enterome Biosciences SA
• Yakult Honsha Co.
• 4D Pharma
• Vedanta Biosciences, Inc.
• Seres Therapeutics
• AOBiome
• Metabiomics Corp.
• Microbiome Therapeutics LLC
• Second Genome
• OptiBiotix HEALTH PLC

第19章 免責事項

Global Human Microbiome Market is expected to grow at a significant rate of around 26.7% during the forecast period. Human microbiome is a collection of microorganisms that live on or within the human body. These microbiomes have shown a potential role in healthcare owing to their multiple functions, including enabling easy digestion, regulation of the immune system, and production of vitamins. Studies have estimated that the number of microbes present inside the human body can be beneficial for the management of several diseases such as cancer and for adopting novel therapies. This presents lucrative opportunities for drug developers and vaccine manufacturers surging the growth of the human microbiome market. Several key companies are getting funds to fasten the process of development of therapeutic drugs. For instance, in 2022, OptiBiotix Health Plc. signed an exclusive sales and distribution agreement with Nahdi medical Co. to help tackle the obesity epidemic.

Enterome Biosciences SA, Yakult Honsha Co., 4D Pharma, Second Genome, Seres Therapeutics, Vedanta Biosciences, Inc., AOBiome, Microbiome Therapeutics LLC, and OptiBiotix HEALTH PLC. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst disease, cancer category to witness higher CAGR during the forecast period"

Based on disease, the market is segmented into obesity, infectious diseases, cancer, autoimmune diseases, metabolic & gastrointestinal disorders, and others. The cancer segment is expected to grow with high CAGR rates during the forecast period. It is attributed to the increase in incidences of cancer and the unmet need for targeted therapy. For instance, Enterome has developed OncoMimics, peptides derived from gut bacteria that mimic tumor-associated antigens in a wide range of cancers. The company's lead candidate, EO2401 is being evaluated in a phase-I/II clinical trial in combination with an immune checkpoint inhibitor for the management of glioblastoma.

"Amongst product type, the probiotics to hold a significant share in the market in 2020"

On the basis of product, the market is categorized into probiotics, prebiotics, diagnostic tests, drugs, medical foods, supplements, and others. Among these, probiotics to hold a significant share of the market in 2020 which is due to the numerous health benefits offered by them. Furthermore, athletes and yoga instructors are also giving emphasis on the health benefits of probiotics through social media and paid partnerships. The segment has also received significant investment, which is another factor propelling the market growth. For instance, in February 2020, Amorepacific Group inaugurated its novel green tea probiotics Research Centre for studying lactobacillus found in Jeju organic green tea.

"Amongst application, diagnostics category to witness higher CAGR during the forecast period"

Based on application, the market is bifurcated into diagnostics and therapeutics. The diagnostic segment is expected to witness high CAGR rates during the forecast period which is due to the rise of scientific and technological innovations in gene mapping and the advent of omics technologies. The companies have also adopted strategic alliances to maintain a strategic edge in the global market. For instance, in June 2022, Genetic Analysis AS entered into collaboration with Servatus Biopharmaceuticals Ltd to advance microbiome diagnostics.

"North America to hold a significant share in the market"

In 2020, North America held a significant share of the global human microbiome market. Several factors, including surge in the prevalence of lifestyle-related disorders, increasing awareness among individuals regarding preventive healthcare, and the rise in research and development of human microbiome are driving the growth of the market in the region. Apart from this, the presence of major key players and the development of a strong pipeline of human microbiome products is also boosting the market's growth. For instance, in 2020, Seres Therapeutics' stool-derived treatment for recurrent Clostridium difficile infection cleared phase III of clinical trials.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

The global human microbiome market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Human Microbiome Market
• 2.2. Research Methodology of the Human Microbiome Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE HUMAN MICROBIOME MARKET

6 HUMAN MICROBIOME MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY Product Type

• 7.1. Probiotics
• 7.2. Prebiotics
• 7.3. Diagnostics Tests
• 7.4. Drugs
• 7.5. Medical Foods
• 7.6. Supplements
• 7.7. Others

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Therapeutics
• 8.2. Diagnostics

9 MARKET INSIGHTS BY Disease

• 9.1. Obesity
• 9.2. Infectious Disease
• 9.3. Autoimmune Diseases
• 9.4. Metabolic & Gastrointestinal Disorders
• 9.5. Cancer
• 9.6. Others

10 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 10.1. Retail Pharmacies
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies

11 MARKET INSIGHTS BY REGION

• 11.1. North America
  • 11.1.1. U.S.
  • 11.1.2. Canada
  • 11.1.3. Rest of North America
• 11.2. Europe
  • 11.2.1. Germany
  • 11.2.2. U.K.
  • 11.2.3. France
  • 11.2.4. Italy
  • 11.2.5. Spain
  • 11.2.6. Rest of Europe
• 11.3. Asia-Pacific
  • 11.3.1. China
  • 11.3.2. Japan
  • 11.3.3. India
  • 11.3.4. Rest of Asia-Pacific
• 11.4. Rest of World

12 HUMAN MICROBIOME MARKET DYNAMICS

• 12.1. Market Drivers
• 12.2. Market Challenges
• 12.3. Impact Analysis

13 HUMAN MICROBIOME MARKET OPPORTUNITIES

14 HUMAN MICROBIOME MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porters Fiver Forces Analysis

18 COMPANY PROFILED

• 18.1. Enterome Biosciences SA
• 18.2. Yakult Honsha Co.
• 18.3. 4D Pharma
• 18.4. Vedanta Biosciences, Inc.
• 18.5. Seres Therapeutics
• 18.6. AOBiome
• 18.7. Metabiomics Corp.
• 18.8. Microbiome Therapeutics LLC
• 18.9. Second Genome
• 18.10. OptiBiotix HEALTH PLC

19 DISCLAIMER